Please login to the form below

Not currently logged in


This page shows the latest Merck news and features for those working in and with pharma, biotech and healthcare.

NICE turns down Opdivo for adjuvant melanoma therapy

NICE turns down Opdivo for adjuvant melanoma therapy

At the moment Opdivo is the only PD-1-targeted cancer immunotherapy approved for adjuvant use, although Merck &Co/MSD’s Keytruda (pembrolizumab) has also shown its value in this setting

Latest news

More from news
Approximately 359 fully matching, plus 1,070 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Checkpoint inhibitors – old and new. The first wave of checkpoint inhibitors targeting PD-(L) 1 and CTLA-4, from Bristol-Myers Squibb, Merck &Co, Roche, AstraZeneca and Merck KGaA/Pfizer, have ... Last year, the FDA approved Merck’s Keytruda

  • Advancing women in healthcare Advancing women in healthcare

    Taking on the mantle of HBA’s Woman of the Year 2018 is Julie Gerberding, Merck &Co’s chief patient officer, and head of global public policy and population health. ... She joined Merck &Co in 2009 and sees her role in promoting vaccines and

  • 30 Women Leaders in UK Healthcare

    2. Louise Houson, MSD UK and Ireland General Manager. L ouise Houson is the first ever woman leader of MSD in the UK and Ireland (known as Merck Inc in North

  • Implementing eHealth innovation Implementing eHealth innovation

    Innovation has driven Merck’s growth and performance to its 350-year celebration in 2018. ... is head of the global business franchise, general medicine and endocrinology at Merck KGaA.

More from intelligence
Approximately 7 fully matching, plus 114 partially matching documents found.

Latest appointments

More from appointments
Approximately 38 fully matching, plus 135 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    Marketing strategy in complex environments. Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through

  • Personalizing customer engagement in pharma

    Personalizing customer engagement in pharma. Barcelona eyeforpharma 2015 highlights: Philippe Kirby, Merck, David Hunt, Havas LYNX, and Richie Bavasso, Agnitio share their views on digital pharma trends. ... Summary/transcript. Barcelona eyeforpharma

  • Novartis CEO on patient value

    Including:. · How GSK, Pfizer and Merck are feeding patient voice, customer insight and point of value into their service strategies for user uplift. · ... You can see the full brochure which drills down in to each session here: . With attendees from

  • Active Life Ahead: Brand Campaign

    Client: Merck Sharp &Dohme.

  • Active Life Ahead: Press Advert

    Client: Merck Sharp &Dohme.

More from PMHub
Approximately 1 fully matching, plus 38 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....